ANDA 215365, held by MSN Laboratories. Fluphenazine Decanoate.
As of Nov 21, 2026, ANDA 215365 (Fluphenazine Decanoate), held by MSN Laboratories, was first approved by FDA on Nov 2, 2023, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE: Fluphenazine Decanoate Injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 2, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluphenazine Decanoate25MG/ML · injectable;injection | Fluphenazine Decanoate | Rx |
| Feb 26, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 2, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters